[1] Brown ZJ, Tsilimigras DI, Ruff SM,et al. Management of hepatocellular carcinoma: A review. JAMA Surg,2023,158(4):410-420. [2] Falette Puisieux M, Pellat A,et al. Therapeutic management of advanced hepatocellular carcinoma:An updated review. Cancers,2022,14(10):2357. [3] Toh MR, Wong EYT, Wong SH,et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology,2023,164(5):766-782. [4] Hong T, Su W, Pan Y,et al. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma. Front Immunol,2022,13:951459. [5] Raja A, Haq F. Molecular classification of hepatocellular carcinoma:prognostic importance and clinical applications.J Cancer Res Clin Oncol,2022,148(1):15-29. [6] Hong M, Tao S, Zhang L,et al. RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol, 2020,13(1):1-16. [7] Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics,2008, 9(1): 1-13. [8] Mascaux C, Angelova M, Vasaturo A,et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature,2019,571(7766):570-575. [9] Wang H, Liu J, Li J,et al. Identification of gene modules and hub genes in colon adenocarcinoma associated with pathological stage based on WGCNA analysis. Cancer Genet,2020,242:1-7. [10] Zhou Y, Zhou B,Pache L,et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.Nat Commun, 2019,10(1),1523. [11] Chandrashekar DS,Karthikeyan SK,Korla PK,et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia, 2022,25:18-27. [12] Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma.J Hepatol,2020,72(2):215-229. [13] Eggert T, Wolter K, Ji J,et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor rrogression. Cancer Cell,2016,30(4):533-547. [14] Melloy PG. The anaphase-promoting complex: A key mitotic regulator associated with somatic mutations occurring in cancer.Genes Chromos Cancer,2020,59(3):189-202. [15] Chen C, Nie D, Huang Y ,et al. Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin-proteasome pathway. J Leukoc Biol,2022,12(4):919-929. [16] Jiang A, Zhou Y, Gong W, et al. CCNA2 as an immunological biomarker encompassing tumor microenvironment and therapeutic response in multiple cancer types.Oxid Med Cell Longev, 2022,2022:5910575. [17] Bendris N, Arsic N, Lemmers B, et al. Cyclin A2, Rho GTPases and EMT. Small GTPases,2012,3(4) :225-228. [18] Guo J, Wu Y, Du J,et al. Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression. Oncogenesis,2018, 7(6): 49. [19] Hao Z, Zhang H, Cowell J. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker.Tumor Biology, 2012 ,33(3):723-730. [20] Xiong Y, Lu J, Fang Q ,et al. UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells.Bioscience reports, 2019,39(4):BSR20182384. |